Company news
Niagen Bioscience, Inc. (NASDAQ:NAGE) news
Every Niagen Bioscience, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Niagen Bioscience to Present at Nasdaq X LD Micro Inaugural SF Summit
August 26, 2026
Niagen Bioscience Expands Tru Niagen® Retail Footprint with GNC and Sam’s Club
August 20, 2026
Niagen Bioscience to Present at the 17th Annual Midwest IDEAS Investor Conference
August 12, 2026
Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168
August 3, 2026
Niagen Bioscience Announces a Newly Published Analysis of Past Clinical Studies Demonstrating Niagen® (Patented Nicotinamide Riboside, NR...
July 28, 2026
Niagen Bioscience to Present at Canaccord Genuity’s 46th Annual Growth Conference
July 27, 2026
Niagen Bioscience to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
July 21, 2026
Niagen Bioscience Appoints Abhijit Kale, Ph.D., as Senior Director of Global External Research
July 16, 2026
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Pro...
July 13, 2026
Niagen Bioscience CEO Rob Fried to Participate in Virtual Fireside Chat to Discuss Pharmaceutical Strategy on July 15, 2026
July 9, 2026
Niagen Bioscience Launches Pharmaceutical Program for Accelerated Aging and Rare Genetic Diseases
July 8, 2026
Niagen Bioscience to Present at the 16th Annual East Coast IDEAS Investor Conference
June 3, 2026
Niagen Bioscience Renames ChromaDex External Research Program to the Niagen Research Program, Strengthening Position as the Global Leader...
June 2, 2026
Niagen Bioscience Announces Participation in Upcoming Investor Conferences
May 8, 2026
Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results
May 6, 2026
Niagen Bioscience Launches Niagen Plus Telehealth Platform, Unveiling At-Home Injection Kit Offering
May 4, 2026
Niagen Bioscience Adds Olympia Pharmaceuticals to 503B Compounding Partner Network for Niagen Plus™
April 28, 2026
Niagen Bioscience to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026
April 22, 2026
Niagen Bioscience Collaborates with USP to Establish First-Ever USP Monograph for Nicotinamide Riboside Chloride (NRCl), the Patented For...
April 9, 2026
Niagen Bioscience Announces First Cruise Ship Clinic Partnership with OneSpa World, Bringing the NAD-Boosting Benefits of Niagen IV to th...
April 1, 2026
Niagen Bioscience Announces First Cruise Ship Clinic Partnership with OneSpaWorld, Bringing the NAD-Boosting Benefits of Niagen IV to the...
March 31, 2026
Niagen Bioscience Increases Share Repurchase Program to $20 Million
March 19, 2026
Niagen Bioscience to Present at the 38th Annual ROTH Conference
March 18, 2026
Niagen Bioscience Surpasses 300 External Research Agreements from Leading Global Institutions on Niagen®, Contributing to 45 Published Cl...
March 17, 2026
Niagen Bioscience Launches Niagen(R) Skincare Innovation Lab and Debuts Dermatologist-Tested Niagen NanoCloud, From Tru Niagen Powered by...
March 11, 2026
Niagen Bioscience Launches Niagen® Skincare Innovation Lab and Debuts Dermatologist-Tested Niagen NanoCloud™, From Tru Niagen Powered by ...
March 10, 2026
Niagen Bioscience Reports 30% Year-Over-Year Net Sales Increase to $129.4 million, 103% Net Income Increase to $17.4 million or $0.22 Bas...
March 4, 2026
Niagen Bioscience to Streamline and Focus its Operations with the Sale of ChromaDex Reference Standards Business to LGC in All-Cash Trans...
February 26, 2026
Niagen Bioscience Secures New U.S. Patent Covering Intravenous and Injection Formulations and Methods of Use for Nicotinamide Riboside (N...
February 25, 2026
Niagen Bioscience is the Premiere Sponsor of the Inaugural "NAD for Health: Opportunities & Challenges" Conference Hosted by the Universi...
February 9, 2026
Niagen Bioscience is the Premiere Sponsor of the Inaugural “NAD for Health: Opportunities & Challenges” Conference Hosted by the Universi...
February 9, 2026
Niagen Bioscience to Report Fourth Quarter and Full Year 2025 Financial Results on Wednesday, March 4, 2026
February 6, 2026
Niagen Bioscience Expands HSA/FSA Access for Tru Niagen®, the Leading NAD+ Supplement in the U.S.*
January 15, 2026
Niagen Bioscience Acquires Existing Core Nicotinamide Riboside (NR) Patent Portfolio from Queen’s University Belfast
December 22, 2025
Niagen Bioscience Launches Tru Niagen® Beauty — The First NAD+ Skincare Supplement in the U.S. Featuring Niagen® (Patented Nicotinamide R...
November 13, 2025
Niagen Bioscience Announces Results from First-Ever Randomized Controlled Trial Exploring Niagen (Patented Nicotinamide Riboside, NR) Sup...
November 12, 2025
Niagen Bioscience Announces $10 Million Share Repurchase Program
November 6, 2025
Niagen Bioscience, Inc. Reports Third Quarter 2025 Financial Results and Reaffirms Increased Full Year Outlook
November 4, 2025
Niagen Bioscience to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
October 21, 2025
Niagen Bioscience Increases Full Year 2025 Net Sales Outlook to 25% to 30% Year-Over-Year Growth
October 6, 2025
Niagen Bioscience's Pharmaceutical-Grade Niagen™ IV and Injections Now Available at over 50 iCRYO Clinics and More than 900 Total Clinics...
October 1, 2025
AboutNADⓇ Debuts as the Leading Online Resource for Scientific Advancements in NAD+
September 16, 2025
Niagen Bioscience, Inc. Reports Second Quarter 2025 Financial Results and Increases Full Year Outlook
August 6, 2025
Niagen Bioscience to Present at Canaccord Genuity’s 45th Annual Growth Conference
August 4, 2025
Niagen Bioscience to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025
July 23, 2025
Niagen Bioscience Announces the Debut of Tru Niagen® and Niagen IV at Equinox Hotel New York
July 14, 2025
Niagen Bioscience Secures Exclusive License to Develop and Commercialize its NAD+ Precursor, Patented Nicotinamide Riboside (Niagen®), as...
July 8, 2025
Niagen Bioscience to Participate at the Roth 15th Annual London Conference
June 20, 2025
Niagen Bioscience to Participate in the BIO 2025 International Convention
June 11, 2025
Niagen Bioscience Announces First-Ever Peer-Reviewed Study Highlighting the Potential of Nicotinamide Riboside (NR) for Werner Syndrome, ...
June 9, 2025